Gedatolisib is approved in combination with fulvestrant, with or without palbociclib ...

This segment explores deeper clinical interpretations of the SERENA-6 trial, particularly focusing on circulating tumor DNA dynamics and their relevance in hormone receptor–positive, HER2-negative ...

FDA approval covers PIK3CA–wild-type HR+/HER2− advanced breast cancer progressing after ≥1 metastatic endocrine line, positioning gedatolisib as a post-endocrine targeted option with fulvestrant ± ...

This segment focuses on the clinical implications of the SERENA-6 trial and its evaluation of circulating tumor DNA–guided treatment switching in hormone receptor–positive, HER2-negative metastatic ...

SAN ANTONIO — Fertility preservation and/or assisted reproductive technologies do not increase the risk for short-term cancer recurrence in young women with early hormone receptor (HR)-positive breast ...

Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients. "We ...

Sacituzumab tirumotecan (sac-TMT) significantly improved progression-free survival compared to chemotherapy in HR-positive, HER2-negative breast cancer patients. Sac-TMT reduced the risk of disease ...

Older women with high-risk hormone receptor-positive breast cancer showed no significant survival benefit from adjuvant chemotherapy 4 or 8 years later. The chemotherapy group experienced four times ...